Sanofi (SNYNF) Goodwill & Intangibles (2009 - 2026)
Sanofi (SNYNF) posted Goodwill & Intangibles of $80.9 billion for Q1 2026, up 2.85% sequentially from $78.6 billion in Q4 2025, and up 20.5% YoY from $67.1 billion in Q1 2025.
Sanofi (SNYNF) Goodwill & Intangibles (2009 - 2026) Analysis & Trends
Sanofi (SNYNF) has 18 years of Goodwill & Intangibles data on file, last reported at $80.9 billion in Q1 2026.
- Quarterly Goodwill & Intangibles rose 20.5% year-over-year to $80.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.9 billion (up 20.5% YoY) and the FY2025 annual result came in at $78.6 billion, up 11.49% from the prior year.
- Goodwill & Intangibles grew to $80.9 billion in Q1 2026 per SNYNF's latest filing, from $78.6 billion in the prior quarter.
- The five-year high for Goodwill & Intangibles was $82.6 billion in Q2 2024, with the low at $67.1 billion in Q1 2025.
- Average Goodwill & Intangibles over 5 years is $76.3 billion, with a median of $78.6 billion recorded in 2025.
- Year-over-year, Goodwill & Intangibles slipped 16.83% in 2025 and advanced 20.5% in 2026.
- Sanofi's Goodwill & Intangibles stood at $73.0 billion in 2022, then increased by 8.69% to $79.3 billion in 2023, then retreated by 11.07% to $70.5 billion in 2024, then rose by 11.49% to $78.6 billion in 2025, then climbed by 2.85% to $80.9 billion in 2026.
- Business Quant data shows SNYNF's Goodwill & Intangibles at $80.9 billion in Q1 2026, $78.6 billion in Q4 2025, and $80.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 80.88 Bn |
| Dec 31, 2025 | 78.64 Bn |
| Sep 30, 2025 | 80.51 Bn |
| Jun 30, 2025 | 68.73 Bn |
| Mar 31, 2025 | 67.12 Bn |
| Dec 31, 2024 | 70.54 Bn |
| Jun 30, 2024 | 82.63 Bn |
| Dec 31, 2023 | 79.32 Bn |
| Jun 30, 2023 | 80.40 Bn |
| Dec 31, 2022 | 72.98 Bn |
| Jun 30, 2022 | 77.40 Bn |
| Dec 31, 2021 | 79.46 Bn |
| Jun 30, 2021 | 77.61 Bn |
| Dec 31, 2020 | 74.86 Bn |
| Jun 30, 2020 | 68.59 Bn |
| Dec 31, 2019 | 67.62 Bn |
| Jun 30, 2019 | 71.37 Bn |
| Dec 31, 2018 | 75.47 Bn |
| Jun 30, 2018 | 1.20 Bn |
| Dec 31, 2017 | 62.81 Bn |